Clinical Trials for Ovarian Cancer

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum‑resistant high‑grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer (1–3 prior lines; prior bevacizumab allowed), ECOG 0–1, measurable disease. Single‑arm regimen adds intermittent relacorilant (selective glucocorticoid receptor modulator to overcome taxane resistance) to nab‑paclitaxel and bevacizumab, given on a 28‑day cycle until progression/toxicity.

ClinicalTrials.gov ID: NCT06906341

Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Patients with Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adult women with measurable, recurrent platinum‑resistant epithelial ovarian cancer (ECOG 0–1; 0–3 prior lines in the platinum‑resistant setting; up to 5 prior lines total; BRCA status known/obtainable), excluding prior PD‑1/PD‑L1, CTLA‑4, CD47/SIRPα therapy or primary platinum‑refractory disease. Therapy combines pegylated liposomal doxorubicin and pembrolizumab with evorpacept (ALX148), a high‑affinity SIRPα‑Fc fusion that blocks CD47 to enhance macrophage‑mediated phagocytosis; treatment is every 21 days with possible maintenance pembrolizumab plus ALX148 after complete response.

ClinicalTrials.gov ID: NCT05467670

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Upfront therapy for adult women with measurable low-grade serous ovarian or primary peritoneal carcinoma who are not candidates for primary cytoreduction or have residual disease after suboptimal debulking. Patients receive avutometinib (dual RAF/MEK clamp) plus defactinib (FAK inhibitor) on a 3-weeks-on/1-week-off schedule with continuous letrozole (and ovarian suppression if pre/perimenopausal).

ClinicalTrials.gov ID: NCT06394804

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; prior bevacizumab and PARP inhibitor as indicated) are randomized to the CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd; cleavable linker to DXd topoisomerase I payload) given IV q3w versus investigator’s choice of weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan. Requires measurable disease, ECOG 0–1, available tumor tissue; excludes prior CDH6/DXd ADCs and patients with active ILD/pneumonitis or significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT06161025

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adult women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (platinum-sensitive or -resistant) with prior PARP inhibitor exposure, ECOG 0–1, and measurable disease. Patients receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT to downregulate HR/MYC programs) plus talazoparib (PARP inhibitor) in 28-day cycles; BRCA status known but not restricted.

ClinicalTrials.gov ID: NCT05071937

Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous ovarian cancer (ECOG 0–1) and measurable disease, typically after bevacizumab, randomized to pegylated liposomal doxorubicin (PLD) with or without NP-G2-044 (prilukae), an oral first-in-class fascin (FSCN1) inhibitor targeting actin bundling/filopodia to reduce motility and potentially enhance antitumor immunity. Excludes primary platinum-refractory or platinum-sensitive disease, significant cardiac/QTc risk, active CNS disease, grade ≥2 neuropathy, severe GI dysfunction precluding oral therapy, extensive liver involvement, uncontrolled effusions/ascites, or prior severe PLD toxicity.

ClinicalTrials.gov ID: NCT07109414

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with high-grade serous epithelial ovarian/fallopian tube/primary peritoneal cancer with radiographic platinum-resistant relapse (progression >3 to ≤6 months after last platinum) after 1–3 prior systemic lines undergo central FRα testing and are enrolled into FRα-high or FRα-low cohorts. Patients are randomized to AZD5335 (torvutatug samrotecan), an FRα/FOLR1-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, versus mirvetuximab soravtansine in FRα-high disease or versus investigator’s choice single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in FRα-low disease.

ClinicalTrials.gov ID: NCT07218809

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant, RECIST-measurable high-grade serous ovarian/fallopian tube/primary peritoneal cancer with CCNE1 (Cyclin E1) overexpression after 1–4 prior systemic lines (with prior bevacizumab and, if FRα-positive, prior mirvetuximab expected) are randomized to INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E1–driven cell-cycle progression, versus investigator’s choice standard single-agent chemotherapy.

ClinicalTrials.gov ID: NCT07214779

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent platinum-sensitive high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal cancer who have completed second-line platinum doublet chemotherapy and have CR/NED, PR, or stable disease (and BRCA-mut/HRD+ patients must have previously received 1L PARP maintenance) are randomized within 8 weeks to maintenance rinatabart sesutecan plus standard-of-care (bevacizumab maintenance if chosen or observation) versus standard-of-care alone. Rinatabart sesutecan is an FRα-targeted antibody–drug conjugate that delivers an intracellular topoisomerase I inhibitor payload to FRα-expressing tumor cells.

ClinicalTrials.gov ID: NCT07225270

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with recurrent or metastatic solid tumors—including endometrial, head and neck, pancreatic, colorectal, hepatocellular, gastric, urothelial, ovarian, cervical, biliary tract, certain subtypes of breast cancer, and cutaneous melanoma—whose disease has progressed after standard therapy and who have measurable, biopsiable disease. All patients receive ifinatamab deruxtecan, an investigational B7-H3-directed antibody-drug conjugate delivering a topoisomerase I inhibitor, administered intravenously every three weeks.

ClinicalTrials.gov ID: NCT06330064